Medical technology company BD (Becton, Dickinson and Company) (NYSE: BDX) announced on Wednesday that it has launched the BD Intraosseous (IO) Vascular Access System, designed to provide rapid vascular access in critical care situations where intravenous (IV) access may be challenging.
This innovative system allows clinicians to administer fluids and medications by inserting a needle into the bone marrow, providing quick access for both adult and paediatric patients.
The BD IO System uniquely features an integrated passive needle tip safety to reduce needlestick injuries and is the only IO device allowing placement after the extension set attachment. With a rechargeable battery that extends drill life up to 12 times over non-rechargeable options, it also includes a multi-light battery indicator for immediate power status assessment. This system demonstrates a 93–97% success rate for trained users and offers higher success in critical cases where low blood pressure hinders standard IV access.
Now available in the US, the BD IO System enhances safety and effectiveness for emergency care providers, furthering BD's commitment to advancing healthcare solutions globally.
Amphix Bio receives USD1m SBIR Phase II grant from National Science Foundation
PharmaNutra signs agreement with strategic consulting firm for US development plan
BD launches advanced Intraosseous Vascular Access System for rapid emergency use
Pulsenmore to supply 25,000 home ultrasound devices to Clalit Health Services
Medtronic announces new, long-term data from SPYRAL HTN-ON MED clinical trial
Senzime unveils next-gen TetraGraph TOF monitor at ANESTHESIOLOGY 2024; US shipments to begin in Q4
Abbott launches new clinical trial to improve results in patients with advanced heart failure
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Adocia patents stable hormone combinations for obesity and diabetes